Absci Raises $100M in Direct Offering with Eli Lilly Participation
Summary
Absci Corp secured $100 million in a direct stock offering, with Eli Lilly & Co. investing $40 million, to fund the clinical development of its lead drug candidate, ABS-201.
Key Events
-
$100 Million Capital Raise
Absci is offering 13,495,277 shares of common stock at $7.41 per share, raising approximately $93.5 million in net proceeds.
-
Strategic Investor Participation
Eli Lilly and Company is purchasing 5,398,111 shares for $40 million, signaling strong confidence in Absci's pipeline.
-
Funding Clinical Advancement
Proceeds will primarily fund the advancement of ABS-201, an AI-designed anti-PRLR antibody, for androgenetic alopecia and endometriosis.
-
Dilution to Shareholders
The offering will result in an 8.68% increase in outstanding shares, causing immediate dilution to existing shareholders.
Analysis
This offering provides Absci with substantial capital to advance its lead drug candidate, ABS-201, for androgenetic alopecia and endometriosis. The participation of Eli Lilly and Company, a major pharmaceutical firm, in this direct offering serves as a significant validation of Absci's AI-designed therapeutic approach and pipeline, especially following recent positive Phase 1 data for ABS-201. While the offering is dilutive to existing shareholders, the capital infusion is critical for extending the company's cash runway and funding key clinical programs, which is particularly important given the company's recent Q1 revenue decline and net losses.
At the time of this filing, ABSI was trading at $10.08 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $2.24 to $11.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.